EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> MorphoSys obtained an option on Vivoryon Therapeutics’ small molecule QPCTL inhibitors in the treatment of cancer. The deal sees MorphoSys commit to take a €15 million ($17 million) stake in Vivoryon as part of an upcoming financing round. Statement

> Acacia Pharma detailed plans to refile for approval of Barhemsys in the third quarter. The disclosure of the plan follows a meeting with the FDA. Release  

> UniQure shared 36-week data on its hemophilia B gene therapy AMT-061. The mean FIX activity in the three patients treated with AMT-061 was 45% of normal. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Freeline posted 12-month data on its hemophilia B gene therapy. FIX activity came in around 40%, but Freeline hopes to ramp that up to 50% to 150% once it optimizes the dose. Release 

> Vasopharm raised €9.5 million to fund work in support of a planned filing for approval of ronopterin. The German company is testing the allosteric iNOS inhibitor in traumatic brain injury patients. Statement 

> Redx Pharma sold a pan-RAF inhibitor to Jazz Pharmaceuticals for $3.5 million upfront. The deal for the preclinical oncology program includes $203 million in milestones. Release 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.